Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACA: nebulised rtPA in COVID-19 ARDS
2020-001640-26Phase 2Unknown
- Sponsor
- University College London
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tissue-plasminogen activator in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by University College London. Primary endpoints: Efficacy of nebulised rtPA and WHO ordinal scale of clinical improvement. Status: unknown.
02
Drugs
tissue-plasminogen activator
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001640-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001640-26.